Dec 12 (Reuters) – Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli Lilly’s experimental weight‑loss pill, after the company pushed for a faster timeline, documents seen by Reuters show.

The FDA Commissioner’s Office has said it wants to cut the time reviewers spend checking whether drug applications have enough material from 60 days to one week for Lilly’s pill and other medicines under a new, speedy review pathway, according to ‍the internal documents.

After internal pushback, the Commissioner’s Office said it may cut those filing reviews to two or three weeks based on the application’s complexity, though Reuters could not confirm whether any change was likely to be implemented and the situation has been fast mov

See Full Page